- Home
- INTS vs IMCC Comparison
INTS vs IMCC Comparison
Compare INTS & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- IMCC
- Stock Information
- Founded
- INTS 2012
- IMCC 1980
- Country
- INTS United States
- IMCC Israel
- Employees
- INTS N/A
- IMCC N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- INTS Health Care
- IMCC Health Care
- Exchange
- INTS Nasdaq
- IMCC Nasdaq
- Market Cap
- INTS 10.9M
- IMCC 12.2M
- IPO Year
- INTS 2023
- IMCC N/A
- Fundamental
- Price
- INTS $0.23
- IMCC $1.97
- Analyst Decision
- INTS Strong Buy
- IMCC
- Analyst Count
- INTS 4
- IMCC 0
- Target Price
- INTS $4.50
- IMCC N/A
- AVG Volume (30 Days)
- INTS 4.0M
- IMCC 70.8K
- Earning Date
- INTS 11-12-2025
- IMCC 11-13-2025
- Dividend Yield
- INTS N/A
- IMCC N/A
- EPS Growth
- INTS N/A
- IMCC N/A
- EPS
- INTS N/A
- IMCC N/A
- Revenue
- INTS N/A
- IMCC $38,430,631.00
- Revenue This Year
- INTS N/A
- IMCC $47.12
- Revenue Next Year
- INTS N/A
- IMCC $12.83
- P/E Ratio
- INTS N/A
- IMCC N/A
- Revenue Growth
- INTS N/A
- IMCC 5.08
- 52 Week Low
- INTS $0.19
- IMCC $1.29
- 52 Week High
- INTS $4.30
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- INTS 32.86
- IMCC 39.04
- Support Level
- INTS $0.27
- IMCC $1.74
- Resistance Level
- INTS $0.30
- IMCC $2.03
- Average True Range (ATR)
- INTS 0.02
- IMCC 0.26
- MACD
- INTS -0.00
- IMCC -0.01
- Stochastic Oscillator
- INTS 6.39
- IMCC 43.29
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.